SCHEDULE: Janus Henderson Boosts Avidity Biosciences Stake to 5.5%
Beneficial Ownership Report
Janus Henderson Group plc has filed an amendment to its Schedule 13G, disclosing a beneficial ownership of 5.5% in Avidity Biosciences, Inc. common stock.
Summary
- Janus Henderson Group plc, a Jersey-based parent holding company and investment adviser, has filed an Amendment No. 4 to its Schedule 13G.
- The filing reports beneficial ownership of 8,224,930 shares of Avidity Biosciences, Inc. common stock.
- This represents 5.5% of Avidity Biosciences' class of securities.
- The event requiring this filing occurred on November 28, 2025, with the statement signed on December 5, 2025.
- Janus Henderson's subsidiaries, including JHIUS, JHIUKL, and JHIAIFML, are registered investment advisers that furnish investment advice to Managed Portfolios.
Sentiment
Score: 5
Explanation: The filing is a neutral, factual disclosure of beneficial ownership, providing no direct positive or negative sentiment regarding the issuer's performance or prospects.
Positives
- N/A This filing is a factual disclosure of beneficial ownership and does not contain information on the issuer's performance or outlook.
Negatives
- N/A This filing is a factual disclosure of beneficial ownership and does not contain information on the issuer's performance or outlook.
Risks
- N/A This filing is a factual disclosure of beneficial ownership and does not detail risks specific to the issuer.
Future Outlook
N/A This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the issuer.
Industry Context
This filing indicates continued or adjusted institutional interest in Avidity Biosciences, a company operating in the biotechnology sector. Such disclosures are common for publicly traded companies and reflect investment decisions by large asset managers.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, which can influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 2022-12-09 | Date of execution of the Power of Attorney by Janus Henderson Group plc. |
| 2025-11-28 | Date of event which required the filing of this statement (beneficial ownership threshold crossed or changed). |
| 2025-12-05 | Date the Schedule 13G Amendment No. 4 was signed by Janus Henderson Group plc. |
Keywords
Avidity Biosciences, Janus Henderson Group, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Investment Adviser, Biotechnology, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.